Marsoni, Silvia

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 1,623

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 1,016

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 939

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

Bertocchi, A., Carloni, S., Ravenda, P. S., Bertalot, G., Spadoni, I., Lo Cascio, A., Gandini, S., Lizier, M., Braga, D., Asnicar, F., et al. (2021) · Cancer Cell

Cancer Cells and MetastasisGut microbiota and health

Cited by 515

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.

Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 504

The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer

Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 479

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., et al. (2013) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 475

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesPI3K/AKT/mTOR signaling in cancer

Cited by 191

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyColorectal Cancer Treatments and Studies

Cited by 115

Long-Term Clinical Outcome of Trastuzumab and Lapatinib for HER2-Positive Metastatic Colorectal Cancer

Tosi, F., Sartore-Bianchi, A., Lonardi, S., Amatu, A., Leone, F., Ghezzi, S., Martino, C., Bencardino, K., Bonazzina, E., Bergamo, F., et al. (2020) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 101

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance

Amodio, V., Lamba, S., Chilà, R., Cattaneo, C. M., Mussolin, B., Corti, G., Rospo, G., Berrino, E., Tripodo, C., Pisati, F., et al. (2023) · Cancer Cell

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 39

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial

Siena, S., Sartore-Bianchi, A., Personeni, N., Pietrantonio, F., Germano, G., Amatu, A., Bonoldi, E., Valtorta, E., Barault, L., Di Nicolantonio, F., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 15